
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Clinerion and Massive Bio have partnered to improve trial site selection and offer better access for cancer patients to clinical trials. Clinerion’s Patient Network Explorer queries anonymized patient data from its network of partner hospitals to deliver real-world health data insights useful for Massive Bio’s site outreach programs.
To learn more about their partnership, click






